<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146799">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189396</url>
  </required_header>
  <id_info>
    <org_study_id>API-A006-CL-C</org_study_id>
    <nct_id>NCT01189396</nct_id>
  </id_info>
  <brief_title>Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006</brief_title>
  <official_title>A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic
      profiles of A006, in comparison with those of an active control, Proventil®-HFA MDI, and a
      placebo control DPI, in escalating and cumulative-doses up to 1,440 mcg, eight (8) times of
      the proposed clinical dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchodilatory efficacy after the escalating and cumulative-doses, up to 1,440 mcg.</measure>
    <time_frame>-15 min predose, 15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, 360 min post dose 4</time_frame>
    <description>Area Under the Curve (AUC)0-t of percent change in Forced Expiratory Volume in 1 second (FEV1), which is defined as the area under curve of post-dose FEV1 percentage changes from the Pre-dose Baseline FEV1 (FEV10) versus time. Doses are at 0, 30, 60 and 90 min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of change in FEV1</measure>
    <time_frame>-15, 15 min post 1, 2, and 3, and 15, 90, 120, 240, and 360min post dose 4</time_frame>
    <description>AUC of FEV1 volume post-dose changes (change in Volume) from the Pre-dose Baseline FEV1 (FEV10). Doses are at 0, 30, 60 and 90 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset</measure>
    <time_frame>0 - 120 min</time_frame>
    <description>Time to onset of bronchodilatory effect, determined by linear interpolation as the point where FEV1 % change first reaches ≥ 12% from FEV10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Response</measure>
    <time_frame>15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, and 360 min post dose 4</time_frame>
    <description>The peak bronchodilator response, defined as the maximum post-dose FEV1 % change. Doses are at time 0, 30, 60, and 90 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Time 0, 15, 45, 75, 105, 150, 195, 130, 190, 250, 435 minutes post dose 1</time_frame>
    <description>The adverse drug events (ADE) that are observed with Albuterol MDI may be expected with the use of Albuterol DPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Analysis</measure>
    <time_frame>-15, 10, 25,40, 55, 70, 85, 95, 115, 145, 175, 210, 270, 330, 690 min post dose 1</time_frame>
    <description>serum glucose and potassium analysis and PK analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs and Electrocardiogram (ECG)</measure>
    <time_frame>-15, 5, 35, 65, 100, 155, 275, 455, 815 min post dose 1</time_frame>
    <description>vital signs, including pulse and blood pressure and 12-lead ECG</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Asthma</condition>
  <condition>Bronchospasm</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albuterol Inhalation Powder escalating dose up to 180 mcg/dose, cumulative dose up to 1440 mcg, dosing at 30 min. intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proventil HFA albuterol inhalation aerosol, 90 mcg/ inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control, 0 mcg albuterol/dose, contains only lactose as carrier.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol Inhalation Powder</intervention_name>
    <description>Albuterol dry powder inhaler, 180 mcg/inhalation, escalating dose 180 mcg, 180 mcg, 360 mcg, 720 mcg, at 30 min intervals, total cumulative dose 1440</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <other_name>A006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Placebo control contains only lactose in amounts identical to the lactose contained in A006. 1, 1, 2, and 4 inhalation at 30 min intervals.</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>Proventil HFA albuterol inhalation aerosol, 90 mcg/inhalation, 2, 2, 4, and 8 inhalations per dose a 30 min intervals, total accumulated dose 1440 mcg.</description>
    <arm_group_label>Active Control</arm_group_label>
    <other_name>albuterol inhalation aerosol HFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ≥ 50 kg for men and ≥ 45 kg for women, and BMI within the range of 18.5 -
             30.0 kg/m2 inclusive;

          -  Sitting blood pressure ≤ 135/90 mmHg;

          -  Demonstrating negative alcohol/drug screen tests;

          -  Demonstrating negative HIV, HBsAg and HCV-Ab screen tests;

          -  With mild-to-moderate persistent asthma for at least 6 months prior to Screening, and
             having used inhaled β-agonist(s) for asthma control;

          -  Demonstrating a Mean Screening Baseline FEV1 at 50.0 - 85.0 % of predicted normal;

          -  Demonstrating a ≥ 15.0% Airway Reversibility in FEV1 within 30(±5) min after inhaling
             2 actuations of Proventil® MDI;

          -  Demonstrating Peak Inspiratory Flow Rate within 80-150 L/min;

          -  Demonstrating proficiency in the use of DPI and MDI after training;

          -  Females of child-bearing potential must be non-pregnant, non-lactating, and
             practicing a clinically acceptable form of birth control;

          -  Having properly consented to participate in the trial.

        Exclusion Criteria:

          -  Smoking history of ≥ 10 pack-years, or having smoked within 6 months prior to
             Screening;

          -  Upper respiratory tract infections within 2 wk, or lower respiratory tract infection
             within 4 wk;

          -  Asthma exacerbations that required emergency care or hospitalized treatment, within 4
             wk prior;

          -  Any current or recent respiratory conditions that might significantly affect
             pharmacodynamic response to the study drugs, besides asthma;

          -  Concurrent clinically significant cardiovascular, hematological, renal, neurologic,
             hepatic, endocrine, psychiatric, malignancies, or other illnesses that could impact
             on the conduct, safety and evaluation of the study;

          -  Known intolerance or hypersensitivity to any of the ingredients of the study drug DPI
             or Proventil® MDI;

          -  Use of prohibited drugs or failure to observe the drug washout restrictions;

          -  Having been on other clinical drug/device studies in the last 30 days;

          -  Having donated blood within the last 30 days prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Amphastar Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphastar Site 4</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 1</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ampahstar Site 3</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ampahstar Site 2</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahrens RC. The role of the MDI and DPI in pediatric patients: &quot;Children are not just miniature adults&quot;. Respir Care. 2005 Oct;50(10):1323-8; discussion 1328-30. Review.</citation>
    <PMID>16185368</PMID>
  </reference>
  <reference>
    <citation>Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur J Clin Pharmacol. 1987;32(6):631-4.</citation>
    <PMID>3653233</PMID>
  </reference>
  <reference>
    <citation>Hindle M, Newton DA, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. Chest. 1995 Mar;107(3):629-33.</citation>
    <PMID>7874928</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force.. General considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. Review.</citation>
    <PMID>15994402</PMID>
  </reference>
  <reference>
    <citation>Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68.</citation>
    <PMID>16264058</PMID>
  </reference>
  <reference>
    <citation>Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981 Jun;123(6):659-64.</citation>
    <PMID>7271065</PMID>
  </reference>
  <reference>
    <citation>Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir. 1982 May-Jun;18(3):419-25.</citation>
    <PMID>7074238</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 23, 2012</lastchanged_date>
  <firstreceived_date>August 24, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Amphastar Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>bronchospasm</keyword>
  <keyword>COPD</keyword>
  <keyword>reversibility</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Bronchial Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
